# Proteome Sciences plc Look forward to strong progress during 2018

- Link: https://www.directorstalkinterviews.com/proteome-sciences-plc-look-forward-strong-progress-2018/412749883
- Published: 2018-04-24T07:28:11+01:00
- Author: Giles Arbor

**Proteome Sciences plc** (LON:PRM) has today announced its audited results for 
the year ended 31 December 2017.

**Highlights:**

· 23% revenue growth to £3.38m, underpinned by 79% increase in sales and royalties
attributable to TMT® reagents.

· Appointment of our first Chief Commercial Officer in April 2017 to relaunch the
biomarker services business which has led to the engagement of sales agents in our
principal operating territories.

· Closure of the London laboratory in June 2017, with consolidation of all equipment
and capabilities at our existing Frankfurt facility.

· Relocation of the Company headquarters from Cobham to the ‘knowledge quarter’ 
in central London

· Receipt of Good Clinical Laboratory Practice (GCLP) accreditation in October 2017
enabling our engagement in clinical stage contracts.

· Achievement of research milestone following the presentation of data from a prospective
trial using the Randox Rapid Stroke Array.

**Post year-end:**

Extension of our exclusive licence agreement with Thermo Scientific to include patents
relating to a new class of high-plex TMT® reagents.

> **Jeremy Haigh, Chief Executive Officer of Proteome Sciences plc, commented:**“
> 2017 was a year of significant change inside the Company with the successful implementation
> of numerous strategic initiatives and steady progress towards our financial goals.
> With the benefits of a leaner organisation, a new model for commercial engagement
> deployed in both our principal operating territories, and the reassurance of robust
> demand for our TMT® reagents, we now have the platform necessary to realise the
> full value of our proteomic capabilities. We look forward to strong progress during
> 2018, particularly growth in our biomarker services business, and to providing
> further updates during the course of the year.”

**Chief Executive Officer’s Statement**

After a year of significant change inside the company, and profound economic uncertainty
outside, I am pleased to report a solid 12 months ending 31 December 2017. Revenue
increased 23% to £3.38m, including a 79% increase in sales and royalties attributable
to isobaric tandem mass tag (TMT®) reagents. Total costs reduced by 4.5% to £5.43m
reflecting the early impact of consolidating our facilities and restructuring, which
itself generated one-off costs of £0.14m from discontinued operations. Loss before
tax was reduced to £2.05m but remained higher than planned. Cash reserves at the
year-end were £0.91m owing to the payment of a material R&D tax credit being delayed
into 2018.

In the first half of the year we implemented some important elements of the strategy
which had underpinned our fundraise late in 2016, notably those affecting our physical
footprint and internal capabilities. The decision to integrate all laboratory equipment
and competencies at our existing facility in Frankfurt was difficult given our UK
heritage, and unfortunately resulted in the redundancy of four staff members, but
it has certainly enabled more efficient resource utilisation and clearer accountabilities.
The associated relocation of the Company headquarters from Cobham to central London
in June has afforded us much greater connectivity with the UK bioscience community
and is a fundamental requirement for successful partnership and collaboration. I
am pleased that the combination of these two transformational events was achieved
with only minimal cost and business disruption.

Given the critical strategic importance of commercialising our proteomic services
to the future success of the Company, I was delighted to appoint Richard Dennis 
as our first Chief Commercial Officer at the start of April. With a strong background
in sales and marketing, and extensive technical experience gained at several competitor
companies, Richard quickly transformed our commercial identity and ambition with
his focus on face to face selling, account management, and an established client
network across Europe. His arrival heralded a relaunch of our services business 
and inspired a complete review of our commercial practices resulting in the adoption
of an agent-based sales model in our principal operating territories.

With the continuing growth of our TMT® reagents business, through an exclusive licence
with Thermo Fisher Scientific, the Company is now well placed to deliver a hybrid
model of product and service provision which is increasingly favoured in the bioscience
community by customers seeking relationships with organisations capable of broader
engagement.

Like most other sectors in 2017, the life sciences were affected by uncertainty 
surrounding Brexit, the unexpected outcome of the US election and impending tax 
reforms. The combination of these events saw many companies adopt a more conservative
approach than in previous years and this caution was particularly evident in decision
making around outsourcing and collaboration. As a small company trying to establish
a services business we were not immune from the consequences and had to work hard
building new relationships that could generate future revenues. Significant volatility
in foreign exchanges throughout the year affected non-sterling denominated revenues,
as well as those costs associated with our primary facility in Frankfurt, but the
overall effect on EBITDA was neutral.

Staff turnover was higher than in previous years, in part a consequence of the dynamic
environment in which we operate but also of a strategic decision to reduce our operating
costs through natural and forced attrition. As we begin 2018 our budgeted headcount
of 29 will be approximately 30% lower than at the start of 2017. This turnover included
the departure in August of our Finance Director, Geoff Ellis, who had made a significant
contribution to fiscal management and reporting during his three-year tenure. We
are fortunate to have had established employees, in both Stefan Fuhrmann and Victoria
Birse, who were well qualified to assume the roles of Finance Director and Company
Secretary respectively.

After providing outstanding service and scientific insight over 20 years as a Director
of the Company, Prof. William Dawson decided to stand down in the summer. We thank
him for his unique contribution and are delighted to welcome Dr Ursula Ney to the
Board in his place. Dr Ney’s extensive experience of the bioscience industry in 
a range of senior positions within both large and small companies make her ideally
suited to a role on the Board at this pivotal stage in the Company’s evolution.

I would like to thank all the staff who worked for Proteome Sciences during the 
course of 2017, including those who have since left the Company, and trust that 
we can continue to realise the value of their collective contributions.

**Services:**

The wholescale repositioning of our proteomic services business was a basic tenet
of the revised corporate strategy, and much of the year was spent establishing and
communicating this. Active participation in the Alzheimer’s Association International
Conference (AAIC), held in London during July, served as an effective launch platform
for this revised sales initiative as well as demonstrating a more externally focused
agenda.

A new commercial model was adopted from August in the critical US market using United
BioChannels (UBC) as our sales agent. UBC provides us with introductions to prospective
new customers and broad coverage on both US coasts, replacing direct sales staff
in the region. With the prospect of working primarily on a commission basis, this
model represents a more cost-effective approach to sales generation, and has been
replicated in Europe from the start of 2018 using Cenibra GmbH to access German 
speaking countries. We have also partnered with Science Exchange, a US company which
facilitates rapid, no cost engagement of new customers using pre-negotiated legal
agreements, and Scientist.com, a web-based sales portal. All market support activities
have been moved outside the organisation and will now be purchased as required in
London.

Central to our service provision is the creation of a quality culture which can 
reassure prospective customers and provide a distinctive selling feature. To that
end, we were very pleased to receive Good Clinical Laboratory Practice (GCLP) accreditation
in October, enabling us to compete effectively for clinical stage contracts which
command routinely larger budgets. This, combined with our existing ISO 9001 recertification,
makes our Frankfurt facility uniquely well qualified to provide mass spectrometric
proteomic services to a broad range of clients; the advantages of this are becoming
increasingly evident through unsolicited engagement via our website.

Of course, attracting and retaining new business will only succeed if project execution
matches customer expectations of time and cost as well as quality. The introduction
of a dedicated project management function was a deliberate action to ensure better
cross functional integration, management and communication of our contract service
work; a series of project delivery metrics has been established to reinforce this.

Progress, in terms of explicit revenue generation, was slow in the first half of
the year as might have been predicted while the new commercial model was being introduced,
but we were encouraged by the increasing number of active commercial projects during
the second half. Starting from a very low revenue base we saw quarterly growth from
the second quarter onwards in terms of sales and orders received. The pipeline certainly
looks stronger in Q1’18 both for new customers, interested in proof of concept experiments,
and for existing customers wishing to extend current projects or requesting targeted
assay development in support of forthcoming clinical trials. These enquiries must
now be routinely and quickly converted into substantive work orders so that we can
draw positive conclusions about the longer-term commercial potential of our services
strategy.

**Licences:**

Our exclusive licence to provide Thermo Scientific with isobaric tagging reagents(
TMT®) continues to be mutually beneficial. Strong sales and associated royalty payments
have been essential to our revenue growth and demand increased throughout the year
as TMT® reinforced its market leadership position. Cumulative sales have now exceeded
$25m worldwide, a milestone which triggered a significant additional payment that
we received from Thermo Scientific in the fourth quarter. Scope remains for considerable
further growth as adoption by key opinion leaders spreads to the wider research 
community, and key to this will be the introduction of ‘higher plexing’ reagents
which enable even more efficient sample analyses. Work to identify such new tags
has been conducted in close association with our partners at Thermo Scientific and
we hope that these improvements will start to become available during 2018.

Data from a prospective trial using the Randox Rapid Stroke Array were presented
at the EuroMedLab meeting in Athens in June. The array, which incorporated some 
of our biomarkers, showed excellent performance in identifying stroke from mimic
conditions and healthy controls, and in differentiating between ischaemic and haemorrhagic
strokes. These data were sufficient to trigger an important contractual milestone
with Randox which was announced on 30 June and, more critically, to suggest the 
utility of a future diagnostic including stroke biomarkers covered by our intellectual
property (IP). Given the global incidence of stroke, and the therapeutic liability
associated with inaccurate clinical diagnosis, the market opportunity for such a
diagnostic is considerable. However, a clinical validation study being supported
by Randox, and necessary for their CE (Conformité Européene) marked application,
will now take longer than originally communicated owing largely to the speed of 
patient recruitment; a timeline has yet to be set but is expected to extend into
2019.

**Research:**

The focus on service provision has inevitably constrained our own primary research
activities as we aggressively manage finite resources, but we remain indisputably
a science-based company with a commitment to research through partnerships and collaboration.
We have retained a strong interest in neurodegeneration and oncology, continuing
our investment in commercial assay development which is relevant to these therapeutic
areas (e.g. Clusterin Glycoform; Tryptophan Metabolite) and reflects recent customer
feedback for services which can be readily converted into standard GCLP tools for
use in clinical trials.

Our IP portfolio remains central to the Company’s valuation but continues to be 
the subject of review; deliberate rationalisation has been a goal over the last 
18 months and the number of patent families and, importantly, the cost of their 
maintenance is now more in line with the expectations and resources of a company
our size.

**Outlook:**

With the benefits of a leaner organisation, a new model for commercial engagement
now fully deployed in both our principal operating territories, and the reassurance
of robust and increasing demand for our TMT® reagents, we have the platform necessary
to realise the full value of our proteomic capabilities. The recent extension of
our exclusive license agreement with Thermo Scientific, to include patents relating
to a new class of higher-plex TMT reagents currently under development, affords 
us further optimism.

I am conscious, however, that much remains to be done and that sentiment towards
the Company will depend on positive news from our services business in the first
half of 2018. As we continue to expand our range of enabling technologies we are
confident that our long-term commitment to proteomics, combined with a renewed focus
on the speed, cost and quality of our service delivery, will enable us to remain
competitive in a dynamic market which increasingly encourages companies with broader
service platforms than our own.

Our goals are heavily focused on service revenue growth and establishing enduring
partnerships and collaborations. Customer engagement showed genuine signs of improvement
late in 2017, with an unprecedented number of unsolicited contacts and this has 
continued into 2018 with booked orders in the first quarter worth £0.33m, up 37%
on the same period in 2017.

Quantitative proteomics is essential for translating knowledge about the genetic
basis of disease into practical, targeted therapeutics. Its place in the rapidly
evolving world of drug discovery and development is undeniable, and its relevance
to future transformative technologies, such as those based on artificial intelligence,
assured. We remain committed to that future.

I would like to thank our shareholders for their continued support and look forward
to communicating further progress and significant revenue growth during 2018.

Share on:
